PIRFÉNIDONE VIATRIS 267 mg, film-coated tablet 252 tablets
Active ingredients: PIRFÉNIDONE
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet252 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PIRFÉNIDONE VIATRIS 267 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) avec calendrier PVC (ACLAR RX) polytrifluorochloroéthylène aluminium de 252 comprimé(s)
- Marketing authorisation holder
- VIATRIS (IRLANDE)
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 25 Jul 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66704133CIP73026743CIP133400930267431Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PIRFÉNIDONEcomprimé | 267 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: PIRFENIDONE 267 mg - ESBRIET 267 mg, comprimé pelliculé